Xoma | XOMA - Sales Revenues

Stock Price
41.75
Daily Change
-0.25 -0.60%
Monthly
5.40%
Yearly
54.69%
Q2 Forecast
41.02

Xoma reported $25K in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Agenus USD 34.2M 3.97M Dec/2025
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Ardelyx USD 94.47M 30.74M Mar/2026
aTyr Pharma USD 110.08M 109.89M Dec/2025
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Celldex Therapeutics USD 15K 106K Mar/2026
Curis USD 1.14M 1.41M Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Incyte USD 1.27B 240M Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Novartis USD 13.11B 750M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Prothena USD 51.08M 51.06M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Xoma USD 25K 5M Sep/2024